It was announced in a press release on 22 ndJanuary 2018, that the European Commission has approved Adcetris ®(brentuximab vedotin) for the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) in adults after at least one prior systemic therapy.
The European Medicines Agency ( EMA) Committee for Medicinal Products for Human Use ( CHMP) adopted a positive opinionfor this indication in November 2017. This followed resultsfrom the ALCANZAtrial in which brentuximab vedotin demonstrated significantly superior clinical outcomes in patients with CD30-expressing CTCL versus physician's choice